The Economics of Precision Health for Hospitals — ROI Without a Lab
Adding a genomic service line used to mean a lab, a bioinformatics team, and an 18-month build. Here's the per-report math on doing it under your brand instead.
The barrier to genomic revenue for a hospital was never demand. Patients already ask for it, and clinicians already see where it would help. The barrier was the build — the capital, the accreditation, and the year or more it takes to stand up a lab you may never fully utilise. That equation has changed.
The old math
Doing genomics in-house means paying for the whole stack before you see a single report: sequencing hardware, a bioinformatics team, a curated interpretation layer, quality accreditation, and the 12-to-24-month timeline to assemble it. For most hospitals and clinics that is a capital project competing against every other capital project — and one whose payback depends on volume you have to build demand for at the same time. The result is that a service patients want stays on the roadmap indefinitely.
The white-label math
A white-label model inverts the economics. Instead of buying capacity, you pay per interpreted report and deliver it under your own brand. The capital cost of a lab and a bioinformatics team comes off the table entirely, which means the service can be evaluated on contribution per report rather than on a multi-crore build decision.
Revenue tends to arrive in three layers. The first is the lightest: an AI interpretation overlay on the bloodwork you already run, adding genetic context to routine panels with no change to your collection workflow. The second is direct DNA testing, converted from patients who opt into a deeper profile. The third is full-stack multi-omic work — DNA, microbiome and blood read together — for the patients who want the complete picture. Each layer carries a different price point and a different conversion rate, and they stack.
Model it for your practice
Every practice is different, so rather than quote a single number, the calculator below lets you model your own. It uses India-market assumptions — an AI-overlay rate per report, and conversion rates and ticket sizes for DNA and full-stack profiles — and projects monthly and annual revenue against your patient volume. Adjust the inputs to match your reality.
Calculate your potential
Projected additional monthly revenue
₹16,70,000
per month
Illustrative projections. Actual results vary by practice type and market.
Payback, and where the risk sits
The two variables that move this model most are volume and conversion — not capital, because there isn't any. That is the point. A white-label service line reaches payback in the window it takes to integrate, measured in weeks, and it does so without asking the balance sheet to carry a lab through its ramp. Your brand stays on the report, the patient relationship stays yours, and the interpretation engine is someone else's fixed cost to maintain.
If you want the specifics for your setting — your volumes, your existing panels, your integration path — book a demo and we'll model it with you, or see how the model plays out for hospitals and labs.